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ABSTRACT
Nicotine Sensitization in β-Arrestin 2 Knockout Adolescent Mice
by
Jennifer Aileen Correll
β arrestin-2 is a protein involved in signaling of D2 receptors and plays a mediating role in
sensitization to psychostimulants and the opiate morphine. In this study, 3-4 week old BA-2 KO
and wild type C57/B6 mice received nicotine tartarate (s.c, 0.5 mg/kg free base) for 7 or 14
consecutive days followed by a drug-free period. An acute nicotine challenge followed the drugfree period. Results indicated that the absence of β-arrestin-2 reduced sensitization to nicotine in
Experiment 1. BA-2 KOs eventually demonstrated sensitization in Experiment 2. However,
absence of β-arrestin-2 blocked expression of sensitization on the challenge. After the challenge,
brain tissue was removed and the nucleus accumbens was dissected and analyzed for brainderived neurotrophic factor (BDNF). Results showed that BDNF positively correlated with
behavioral results. These results appear to indicate the importance of the β-arrestin 2 protein in
locomotor sensitization and that dopamine signaling is related to BDNF.
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CHAPTER 1
INTRODUCTION
The neurotransmitter dopamine (DA) is responsible for many functions including reward,
motivation, mood, and motor control (Bibb, 2005; Di Chiara, 1999). Motivation is defined by Di
Chiara (1999) as the process by which an organism responds to a stimulus in relation to its
survival value. Furthermore, the mesolimbic DA pathway is commonly associated with many
psychiatric disorders, including schizophrenia, attention-deficit/hyperactivity disorder,
obsessive-compulsive disorder, and drug addiction (Bibb; Brown et al., 2004; Collins, Wade,
Ledon, & Izenwasser, 2004; Le Foll & Goldberg, 2005). Although other neurotransmitter
systems are involved, the DA system has been implicated in the relationship between reward
pathways and addiction (Bibb; Fonder et al., 2005). All addictive drugs act, at least in part, by
increasing DA release primarily in the nucleus accumbens (NAcc), but it has been shown that
DA plays different roles in behavior in different areas of the brain (Di Chiara et al, 2004; Fonder
et al.).
The drug reward pathway originates with DA cell bodies in the ventral tegmental area
(VTA), located in the midbrain. Rewarding drugs increase signaling in the DA system by
stimulating dopaminergic as well as glutamatergic receptors located on cell bodies in the VTA
that send their projections to the NAcc (Traynor & Neubig, 2005). Additionally, areas in the
striatum and frontal cortex have also been shown to play a role in the addictive properties of
drugs. Dopamine neurons have been shown to play a particularly important role in the increase
of neuronal responding to repeated administration of psychostimulant drugs and to
environmental stimuli that are associated with the positive reinforcing effects of drugs
(Marinelli, Rudick, Hu, & White, 2006).
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Dopamine Receptors
Dopamine binds to two families of receptors, the D1 and the D2. The D1 and D2
families of receptors are both classified as metabotropic receptors (Kolb & Whishaw, 2001).
Metabotropic receptors are coupled to guanyl nucleotide-binding proteins (G proteins) that are
responsible for beginning a cascade of events to open an ion channel and for changing metabolic
activity in the cell. Three separate subunits make up the G protein: the alpha, beta, and gamma.
When a neurotransmitter binds to a metabotropic receptor, the alpha-subunit separates from the
beta and gamma subunits and is free to bind to other proteins in the cell or possibly to an ion
channel to open this channel. Binding to an ion channel creates a change in the flow of ions by
either opening a closed ion channel or, in some instances, closing an open channel. This change
in turn causes the cell’s electrical potential to change in the cell, which can lead to either
depolarization or hyperpolarization of the cell’s potential (Kolb & Whishaw).
β-Arrestin 2 and Dopamine
The proteins β-arrestin 1 and β-arrestin 2 have been shown to be co-localized with D1
and D2 receptors, respectively, and have shown to be associated with G-protein signaling at each
receptor. These two proteins have been shown to be responsible for receptor internalization and
signal termination in both D1 and D2 receptors (Beaulieu et al, 2005; Bohn, Gainetdinov, &
Caron, 2004; Zhang, et al., 2005). Both β-arrestins are expressed in neuronal tissues and are
primarily concentrated in postsynaptic regions (Zuo, 2005). β-arrestin 1 and β-arrestin 2
perform some of the same functions, and are similar in that they are isoforms that share structural
similarities and similar amino acids (Zhang et al). Both arrestins have also been shown to hinder
G-protein coupling by inhibiting the hydrolysis of guanosine triphosphate (GTP) to guanosine
diphosphate (GDP), which is the first step in the G-protein coupling signal cascade. For
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example, when a receptor is exposed to an agonist, the β-arrestins are ultimately involved in the
desensitization of the receptor (Dewire, Ahn, Lefkowitz, & Shenoy, 2007). Therefore, the βarrestin molecule associates with receptors that are activated in order to block continued
signaling (Grady, 2007). β-arrestins have been shown to be involved with a number of G-protein
coupled receptors. Of particular importance to this study, β-arrestin-2 has been shown to be
primarily involved in G-protein signaling at the D2 receptor as well as the µ opiate receptor. The
opiate and dopaminergic neurotransmitter systems have been strongly implicated in mediating
addiction to several addictive drugs.
Recent work has also shown that β-arrestin-2 plays a role in signal transduction, and can
phosphorylate receptors on its own (Lefkowtiz & Shenoy, 2005). This is depicted below in
Figure 1. β-arrestin-2 plays a role in both receptor desensitization that is involved in regulating
second messenger signaling as well as regulating signal transduction that is mediated by, for
example, MAP kinases and tyrosine kinases. Thus, it appears that β-arrestin-2 plays a
multifaceted role in cell signaling that in general is regulatory but can also be involved in
phosphorylation of the ion channel itself. Therefore, it can play a direct in the cell response.

Figure 1. Depiction of the role of β-arrestin-2 in the cell response from the dopamine D2 and µ
opioid receptor.
8

β-Arrestin 2 and Addiction
Research has examined the role β-arrestin 2 plays in cocaine and morphine locomotor
sensitization, using a genetic knockout for β-arrestin-2 in the mouse (Bohn et al., 2004; Hack,
Bagley, Chieng, & Christie, 2005; Raehal, Walker, & Bohn, 2005; Zuo, 2005). A genetic
knockout is an animal that is lacking a particular gene, and knockouts have been found to be
particularly useful in gaining information about how a particular system operates when it is
lacking an important component. Not only can information be gathered surrounding the function
of the particular gene, but also it is possible to better understand brain plasticity when the
particular gene is absent (Bohn et al., 2004; Zuo). For example, tolerance to morphine has been
shown though enhanced and prolonged analgesic effects of morphine in β-arrestin 2 knockout
mice (BA-2 KO; Zuo). However, whereas wild type controls became tolerant to acute and
chronic morphine administration, BA-2 KOs continued to sensitize to morphine (Zuo). This
result appears to indicate that the presence of β-arrestin-2 plays a role in tolerance to opiate
drugs, and when not present, G-protein coupling that occurs at the µ opioid receptor continues to
increase with continued administration of the drug. Essentially, knockout of the β-arrestin 2
protein increased sensitivity of µ opioid receptors. In further support of this notion, mice were
also monitored for changes in responsiveness to pain when morphine was administered. To test
pain responsiveness to morphine, mice were tested on a hot-plate test of antinociception,
and BA-2 KOs exhibited a slower paw withdrawal after they have been exposed to morphine as
compared to controls (Bohn et al.). This is actually congruent with locomotor sensitization
results to morphine, in that BA-2 KOs are showing increases in sensitivity of the µ opiate
receptor, which appears to be increasing their threshold to pain.
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Cocaine is a drug in the psychostimulant class and has now been well characterized in its
mode of action in the brain. Cocaine blocks the DA transporter with high affinity, meaning that it
is a very effective drug at blocking reuptake of DA at the synapse. Increases in DA activity are
typically positively correlated with increases in overall locomotor activity. When exposed to
cocaine, mice were examined for increases in locomotor activity because increases in these
behaviors are most commonly associated with psychostimulant administration in rodents (Bohn
et al., 2004). When cocaine was administered to BA-2 KO mice, there was not an increase in
locomotor activity but, in fact, a slight, but nonsignificant, decrease in response to acute cocaine
administration (Bohn et al.; Gainetdinov et al., 2004). However, BA-2 KO mice demonstrated
normal sensitization to chronic cocaine administration that was not significantly different from
wild type controls (Gainetdinov et al.). The reduction in activity to initial cocaine administration
could imply that knockout of β-arrestin 2 blocks the rewarding effects of acute cocaine;
however, there is no current research on any other psychostimulant with BA-2 KOs.
The Dopamine Reward System: The Role of Dopamine Receptors
The pathway between the VTA and the NAcc is critical for behavioral responses to
psychostimulant drugs (Di Chiara, 1999; Vezina, 2004). Studies have shown that the
VTA/NAcc pathway mediates locomotor activity and drug self-administration of the
psychostimulants nicotine, cocaine, amphetamine, and methamphetamine (Vezina, 2004).
Additionally, ablation of either of these areas has been found to create a disruption in selfadministration behavior of these drugs in animals (Jones & Wonnacott, 2004). It has been shown
that the D1 receptor plays the more important role in locomotor sensitization to psychostimulant
drugs. Vezina and Stewart (1989a) demonstrated that the D1 receptor antagonist SCH-23390
blocked sensitization to amphetamine but not morphine, while the D2 antagonist pimozide
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blocked sensitization to morphine but not amphetamine. Bilateral injections of SCH-23390 into
the VTA also blocked sensitization to amphetamine, resulting in the hypothesis that the D1
receptor plays the more important role in sensitization to psychostimulant drugs (Vezina &
Stewart, 1989b). Other studies have shown the importance of the D1 receptor in locomotor
sensitization to other psychostimulants, with the general conclusion being that the D1 receptor
plays the more important role in locomotor sensitization to psychostimulant drugs (Harrod et al.,
2004).
Dopamine Reward System: Dopaminergic Pathways
The VTA sends a prominent dopaminergic projection to the NAcc which is comprised of
two distinct subareas: the shell and the core (Di Chiara & Bassareo, 2007). The shell forms a
crescent moon-shaped brain area around the anterior commisure in the basal forebrain and has
also been referred to as the extended amygdala (Di Chiara, 2000). The amygdala is the emotional
center in the brain, and the shell has been hypothesized to be associated with the emotional
aspects of positive reinforcement, as this area sends and receives prominent projections to and
from the amygdala and the prefrontal cortex. The core is located directly around the anterior
commisure and is histologically similar to the ventral striatum. Based on the fact the striatum is
an area that plays an important role in motor function, the core has been hypothesized to mediate
the locomotor activating effects of positive reinforcement, including the locomotor activating
effects of psychostimulant drugs.
Microdialysis studies examining differences in DA transmission in the shell versus the
core have shown that the psychostimulant nicotine increases DA selectively in the shell, but to a
reduced extent in the core (Di Chiara, 1999; Di Chiara, 2002). It has been hypothesized that the
repeated stimulation of DA transmission in the NAcc shell enhances reward-based learning (Di
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Chiara, 1999), and that DA transmission in the NAcc core mediates locomotor sensitization to
psychostimulant drugs, which could signify that nicotine has stronger associative effects.
The prefrontal cortex (PFC) is a brain area that has been associated with knowledge and
cognition and has been hypothesized to play a role in drug craving (Robinson & Berridge, 2003;
Shu-Peng, Moon, Kim, & Myeong, 2004). The PFC, amygdala, and hippocampus are often
referred to as NAcc-related circuitry and play an important role in modulating behavior relating
to natural rewards (Robinson & Berridge). There have been several hypotheses surrounding the
change from recreational drug use to addiction, and it is likely that the PFC plays a vital role in
this transition. The hedonic homeostasis hypothesis centers on drug use as a means to achieve a
“high” and continued use after addiction as a means to avoid withdrawal (Robinson & Berridge).
It is important to consider that drug exposure over time becomes associated with particular cues
because of its positive reinforcing characteristics. Researchers have posited the aberrant learning
hypothesis which focuses more heavily on natural rewards. The roles played by NAcc-related
circuitry in motivation and behavior could be increased by drugs of abuse and the learning
mechanisms involved in addiction could contribute to impulsivity and relapse (Di Chiara &
Bassareo, 2007; Robinson & Berridge). Interestingly, doses of nicotine that successfully
stimulate DA transmission in the NAcc shell have not been shown to increase DA transmission
in the medial PFC, an area where DA neurons terminate (Di Chiara, 1999).
The Opiate System and its Role in Drug Reward
Three different types of opiate receptors have been discovered, and each of these
receptors binds to different opiates (Feldman, Meyer, & Quenzer, 1997). Particularly relevant to
this study is the µ-receptor, which has a high affinity for morphine. Binding to this receptor
occurs in a variety of brain areas, many of which have been implicated in drug reward, including
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the striatum, NAcc, amygdala, and hippocampus (Feldman et al.). The µ-receptor plays a major
role in morphine analgesia and positive reinforcement associated with opiates.
The Opiate System and its Effects on DA Release
Opiate receptors play a role in DA release by altering DA cell firing or acting in terminal
areas (Feldman, Meyer, & Quenzer, 1997). Dopamine release from the VTA into the NAcc can
be stimulated through DAMGO, a µ-opioid receptor agonist or DPDDE a δ-receptor agonist.
Other opioid receptor agonists were showed to have no influence on DA levels (Feldman et al.,
1997). Opiates can affect DA levels in the terminal areas when an agonist is infused directly into
the NAcc. The µ-agonist have been shown to have no effect when infused directly into the
NAcc, however, δ-receptor agonists did stimulate DA flow (Feldman et al.).
Nicotine
Nicotine is an agonist at the nicotinic receptor. There are various types of nicotinic
receptors in the central and peripheral nervous system (Pierce & Kumaseran, 2007). These
subtypes are divided into two ligand binding sites, alpha (α) and beta (β), and receptors are made
up of a combination of these subunits with the exception of the α7, which has no β subunit
(Pierce & Kumaseran). In the brain, there are a high number of nicotinic receptors in the VTA,
hippocampus, and frontal cortex. It is apparent that the high concentration of nicotinicacetylcholine receptors (nAChRs) on the cell bodies of the VTA may contribute to dopaminergic
neurotransmission in the NAcc, which has been implicated in the addictive properties of
nicotine.
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The Effects of Nicotine on Dopaminergic Transmission
Laviolette and van der Kooy (2003) have shown that nicotine infusion directly into the
VTA produces a wide range of effects on the rewarding properties of nicotine. Studies by
Wonnacott (2000) and colleagues have shown that blockade of nAChR subtypes in the VTA via
intrabrain infusion of nAChR antagonists blocks DA release in the NAcc and, in turn, blocks
increases in locomotor sensitization to nicotine. Nicotine has also been shown to produce an
increase in mood and arousal, decreased anxiety and appetite, improved attention, and cognitive
enhancement (Cook, Spring, & McCharque, 2007; Pierce & Kumaseran, 2007; Rusted, Trawley,
Heath, Kettle, & Walker, 2005). Like other addictive drugs, nicotine has effects on several
different neurotransmitters. The nicotinic, dopaminergic, and serotonergic systems have all been
implicated in nicotine addiction (Dani, 2003). In addition, nicotine also causes an increase in the
number of nAChRs in several different brain areas (Hernandez & Terry, 2005; Ungless & Cragg,
2006). This increase in nAChRs in the brain could likely affect neurotransmission, as nAChRs
are located both pre- and post-synaptically and have been shown to affect release of several
different neurotransmitters, including DA, acetylcholine, serotonin (5-HT), glutamate, and
GABA (Hernandez & Terry).
Nicotine is highly addictive because of the vast brain areas that are affected by this drug.
Several major systems have been implicated in nicotine addiction (Dani & De Biasi, 2001). One
system originates in the basal forebrain and projects to the cortex and hippocampus, whereas a
second system originates in the tegmentum and projects to the thalamus, substantia nigra. A third
system projects from the VTA to the NAcc and is affected by nicotine because it is an area rich
in DA. (Dani & De Biasi). One of the primary pathways in which nicotine affects several
neurotransmitters is through increasing calcium ionic influx in presynaptic terminals through its
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action on presynaptically located nicotinic receptors. Nicotinic receptors have been shown to be
presynaptically located on DA, 5-HT, and norepinephrine (NE) neurons. Thus, by acting on
presynaptically located nicotinic receptors, it is thought this may be a primary mechanism
through which nicotine acts to influence mood elevation and positive reinforcement
Nicotine and the Opiate System
Opiates and psychostimulants act by either stimulating DA cell bodies or by stimulating
DA synapses (Wise, 1987). Studies have examined the interaction between nicotine and the
opiate system in animals and in humans. Krishnan-Sarin, Rosen, and O’Malley (1999) examined
how the opiate system of adult nicotine users responded to the opioid antagonist naloxone. Nine
smokers and 11 non-smokers were administered various levels of naloxone and watched for
opiate-like withdrawal, nicotine craving, and changes in cortisol levels. Results showed that in
smokers naloxone generated dose dependent increases in withdrawal symptoms with low doses
of naloxone increasing nicotine craving and tiredness. Non-smokers also exhibited lower levels
of cortisol in response to the drug (Krishnan-Sarin et al.).
In animal studies, Watkins, Stinus, Koob, and Markou (2000) examined the nAChR and
opiate receptor role in withdrawal from nicotine. Animals were implanted with a mini-pump
which administered nicotine or saline and the nicotinic antagonists mecamylamine,
chlorisondamine, or dihyro-β-erythroidine or the opiate antagonist, naloxone, were administered
subcutaneously. Conditioned aversion and threshold levels were measured. Animals receiving
naloxone showed physical signs of reward and exhibited reward threshold only at high levels
compared to the nicotinic antagonists. In contrast, naloxone produced conditioned aversion at
significantly lower levels than needed to produce threshold. Therefore, the opiate system
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appears to play a larger role in conditioned aversion related to nicotine withdrawal (Watkins, et
al.).
Nicotine Sensitization
Sensitization occurs when repeated exposure to a stimulus causes an increase in
responding (Traynor & Neubig, 2005). Repeated exposures of psychostimulants have been
found to cause an increase in behaviors associated with the drug (Byrnes & Wallace, 1997). In
studies examining the relationship between nicotine and behavioral sensitization, it has been
found that repeated injections of nicotine produces sensitization in rats after an initial hypoactive
response to the drug (Domino, 2001; Schoffelmeer, De Vries, Wardeh, van de Ven, &
Vanderschuren, 2002). For example, Domino examined three doses (.1, .32, and 1.0 mg/kg) in
adult female rats. Animals receiving .1 mg/kg and .32 mg/kg demonstrated statistically
significant increases in activity compared to controls after six days of drug administration.
Animals that received a pretreatment of dexamethasone, a steroid hormone, before receiving 1.0
mg/kg of nicotine showed statistically higher activity levels than controls (Domino). In addition,
the rewarding effects of nicotine have been found to be persistent. Studies have shown that the
enhancing effects of nicotine are still present after a 2-week abstinence period (Levin, 1992).
Adolescent vs. Adulthood Nicotine Exposure
There have been studies analyzing age differences in nicotine use, especially comparing
adolescent to adult use. The reason for this is that adolescence is an age at which nicotine use
often begins, with 80% of smokers beginning before age 18 (Collins, Wade, Ledon, &
Izenwasser, 2004; Faraday, Elliott, & Grunberg, 2001). Findings have shown that nicotine
dependence beginning in adolescence causes higher rates of dependence and increases in daily
tobacco use, while decreasing the likelihood of cessation in adulthood (Collins et al.; Elliott,
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Faraday, Phillips, & Grunberg, 2005; Faraday et al.). Animal studies on the effects of nicotine in
adolescence have shown that chronic nicotine administration in adolescent male rats produced
long-term hyperactivity that was fundamentally different than adults (Faraday et al.).
Furthermore, male rats that were exposed to nicotine during adolescence were more sensitive to
the activating effects of nicotine when it was administered in adulthood (Faraday, Elliott,
Phillips, & Grunberg, 2003). Unlike male rats, nicotine did not produce long lasting
hyperactivity in female rats (Elliott et al.). Additionally, there was a dose-response difference, in
that adolescent female rats responded to nicotine by increasing activity at two different doses, .5
mg/kg and 1.0 mg/kg, whereas adult females only demonstrated increased activity to the .5
mg/kg dose (Elliott et al.).
Trauth, Seidler, and Slotkin (2000) examined the effects of nicotine exposure in
adolescent rats by administering nicotine though a minipump from postnatal day (PN) 30 to PN
47.5, which corresponds with early and late adolescence in the rat. Results showed that
adolescent exposure produces behavioral and neurochemical changes in adulthood. Female rats
displayed a reduction in grooming during adolescent exposure and a reduction in locomotor
activity and rearing behaviors 2-weeks after cessation, while male rats showed no differences
(Trauth, Seidler, & Slotkin). Additionally, levels of DA and NE were activated, or increased,
after adolescent nicotine exposure (Trauth, Seidler, Ali, & Slotkin, 2001). However, two
criticisms of these studies are that a minipump was used to deliver nicotine, which means that the
drug was constantly delivered throughout adolescence; second, the nicotine dosage used far
exceeded clinically relevant levels.
It has been shown previously that repeated exposure to nicotine produces marked
increases in DA release, serotonin transporter binding, serotonin release and reuptake, (Collins,
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et al., 2004). One hypothesis for the difficulties in smoking cessation for adults whose
dependence began in adolescence could be explained by permanent alterations in
neurotransmitters that occur during adolescence. Supporting this hypothesis is research
performed by Collins and colleagues (2004) which shows that male adolescent rats exposed to
nicotine showed increases in DA transporter densities in the caudate putamen and NAcc while
adult rats did not show changes in DA transporter densities in these areas. Changes in dendritic
spine length in the NAcc have also been found in male adolescent rats (McDonald, et al, 2005).
Animals that received nicotine had significantly longer dendrites and a significant increase in the
number of segments than controls (McDonald, et al.). These results suggest changes in brain
plasticity in response to adolescent nicotine exposure that may be mediating the long-term and
persistent effects of nicotine in adulthood. However, Brown and Kolb (2001) also showed this in
adult rats, so changes may not be a result of age differences but of age similarity.
Neurotrophic Factors
Neurotrophic factors have been shown to mediate the growth of cells in development and
regulate plasticity and survival in adult cells (Shoval & Weizman, 2005). Previous studies have
shown that chronic drug exposure generates changes in brain structure that could lead to
stimulant addiction. Nicotine has been shown to increase both nerve growth factors (NGF) and
brain-derived neurotrophic factors (BDNF) in several brain areas including the hippocampus and
frontal cortex (French et al., 1999; Kenny et al., 2000). BDNF has also been shown to be
activity-dependent and significant increases in cell activity typically produce significant
increases in BDNF (Hennigan, O'Callaghan, & Kelly, 2007).
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Statement of the Problem
β-arrestin-2 is a regulatory molecule in two systems that are involved with and play
primary roles in addiction: the DA and opiate systems. When β-arrestin-2 is not present, because
it is a regulatory molecule, it should increase sensitivity of these receptors. Based on the fact that
β-arrestin-2 is co-localized with and regulates µ opiate receptor and DA D2 receptors, its
absence should increase sensitivity of these receptors and increase responding to drugs that act as
agonists in these systems. Nicotine is an addictive drug in the psychostimulant class, and its
additive properties are mediated by the DA system. Nicotine is known to significantly increase
DA release from the presynaptic terminal. Additionally, there have been age differences in
nicotine effects on behavior, in that nicotine exposure in adolescence produces different
behavioral responses and appears to produce an increased propensity to use nicotine in
adulthood. This study will be designed to produce nicotine sensitization in a BA-2 KO mouse
model. Only male mice will be studied, and all animals will be tested between 3-5 weeks of age,
which is congruent with adolescence in the mouse. It is hypothesized that adolescent BA-2 KO
mice will show decreased locomotor activity after nicotine administration compared to
adolescent wild type mice.
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CHAPTER 2
METHOD
Experiment One
Thirteen male BA-2 KO mice and 18 male wild-type C57/B6 mice that were 3-4 weeks
old at the beginning of testing were used as subjects. Mice were socially housed (2-3 per cage) in
a climate-controlled vivarium with a 12 h light/dark cycle. Food and water were provided ad
libitum. The mice were divided into two groups with the experimental group receiving nicotine
and the control group saline. All injections were given in 1 mg/kg dose. The East Tennessee
State University Committee on Animal Care approved all procedures in this study.
Habituation occurred 1 day before beginning behavioral testing. For habituation, all mice
were given a subcutaneous (s.c.) injection of saline and placed in the locomotor activity chamber
for 30 minutes. A grid of black lines covered the floor of the arena, and horizontal activity was
scored by the number of grid line crossings made by each mouse during each testing session.
Sensitization training began 1 day after habituation was complete. During sensitization testing,
mice were given an s.c. injection of 0.5 mg/kg nicotine tartarate (free base) or saline every day.
After each injection, mice were immediately placed into a locomotor chamber for 10 minutes of
behavioral testing. Behavioral sensitization lasted for 7 days with testing occurring daily over
this period. After the completion of sensitization testing, there was a 1-week abstinence period
during which mice received no drug or saline injections. On day 7 after sensitization testing was
complete, mice in the nicotine group were given a nicotine challenge in which mice in the
nicotine group received an s.c. injection of nicotine and animals assigned to the saline group
received an s.c. injection of saline. They were then placed in the locomotor chamber for 10
minutes and activity was recorded. Tissue was removed the following day for analysis.
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The rationale for a challenge performed 7 days after sensitization testing is based on work
by Kalivas and colleagues. A primary concern in understanding the neural underpinnings of
nicotine-induced sensitization is the time at which behavioral and neurochemical measurements
are obtained after discontinuing long-term drug treatment. It has been suggested that
measurements taken during the first week after drug withdrawal may mask some of the
biochemical alterations underlying behavioral sensitization (Kalivas & Duffy, 1993). For this
reason, it has been suggested that it is most appropriate to measure changes in neural function
following a drug challenge administered a week or more after discontinuing the drug
administration regimen (Pierce & Kalivas, 1997). Therefore, in this experiment, a nicotine
challenge was performed 1 week after repeated nicotine administration has ceased.
Experiment Two
Eight male BA-2 KOs and 21 male wild-type C57/B6 mice that were 3-4 weeks old at the
beginning of testing were used as subjects. Mice were socially housed (2-3 per cage) in a
climate-controlled vivarium with a 12 h light/dark cycle. Food and water were provided ad
libitum. The mice were divided into two groups with the experimental group receiving nicotine
and the control group saline. All injections were given in 1 mg/kg dose. The East Tennessee
State University Committee on Animal Care approved all procedures in this study.
Habituation occurred 1 day before beginning behavioral testing. For habituation, all mice
were given a subcutaneous (s.c.) injection of saline and placed in the locomotor activity chamber
for 30 minutes, and activity was analyzed across three consecutive 10 min sessions, which acted
as the repeated measure. A grid of black lines covered the floor of the arena, and horizontal
activity was scored by the number of grid line crossings made by each mouse during each testing
session. Sensitization training began 1 day after habituation was complete. During sensitization
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testing, mice were given an s.c. injection of 0.5 mg/kg nicotine tartarate (free base) or saline
every day. After each injection, mice were immediately placed into a locomotor chamber for 10
minutes of behavioral testing. Behavioral sensitization lasted for 2-weeks with testing occurring
daily over a 14-day period. After the completion of sensitization testing, there was a 1-week
abstinence period during which mice received no drug or saline injections. On day 7 after
sensitization testing was complete, mice in the nicotine group were given a nicotine challenge in
which mice in the nicotine group received an s.c. injection of nicotine and animals assigned to
the saline group received an s.c. injection of saline. They were then placed in the locomotor
chamber for 10 minutes and activity was recorded. Tissue was removed the following day for
analysis.
BDNF Analysis
Twenty-four hours after the nicotine challenge, brains were harvested and flash frozen in
isopentane before being stored at -80°c. The nucleus accumbens and occipital cortex were
dissected and homogenized in a RIPA cell lysis buffer. Following homogenization, tissue
samples were analyzed using a BDNF Emax Immunoassay system (Promega, Madison, WI).
Optical density was measured using a 96-well Bio-Rad plate reader.

22

CHAPTER 3
RESULTS
Experiment 1
The primary statistic used was the ANOVA, and all post hoc comparisons were
performed using Fisher’s LSD post hoc tests. The independent variables were genetic mutation
(wild type or BA-2 KO), drug treatment (nicotine or saline), and day of treatment (7 days). The
dependent variable was number of horizontal line crosses. Three different time points were
analyzed: The habituation period, the 7-day sensitization training sessions, and the nicotine
challenge. For habituation, a 2 x 2 x 3, three-way repeated measures ANOVA revealed a
significant main effect of repeated measure (F(1,59)=86.33, p<.001). Both the BA-2 KO and
wild-type mice demonstrated significant decrease in activity over the 30 min period, but there
were no significant differences between wild types and BA-2 KO mice.
For sensitization training sessions (presented in Figure 2), a 2 x 2 x 7 three-way repeated
measures ANOVA was used, with each of the 7 days of testing representing a separate level of
the day of treatment repeated measures independent variable. This ANOVA revealed a
significant main effect of both drug treatment (F (1, 26) =4.65, p<.04) and mutation (F (1, 26) =
15.74, p<001), and a significant two-way interaction of Drug Treatment x Day of Testing (F (6,
26) =4.45, p<.001). Nicotine produced an initial hypoactivity in the wild type controls, and over
days produced a significant increased in horizontal activity in the wild type control mice to the
levels of the saline-treated wild types. However, nicotine-induced hypoactivity in the BA-2 KO
mice at Days 3 and 4 and BA-2 KOs demonstrated significant hypoactivity to wild types
throughout testing. Thus, BA-2 KO mice demonstrate nicotine-induced decreases in locomotor
activity.

23

Figure 2. Seven-day drug training.
For the nicotine challenge (see Figure 3) a 2 x 2 two-way ANOVA revealed a significant
main effect of mutation (F (1, 27) = 17.771, p<.01), and a significant interaction of Drug x
Mutation (F (1, 27) = 4.225, p<.04). Nicotine induced hypoactivity in BA-2 KO mice relative to
all other groups, replicating the nicotine-induced hypoactivity at Days 3 and 4 during
sensitization training. Interestingly, nicotine induced a significant increase in activity in wild
types on the challenge, whereas this did not occur during sensitization training. Finally, the BA-2
KO mutation induced an overall hypoactive response as compared to wild types.
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Figure 3. Experiment 1 nicotine challenge.
Experiment 2
The primary statistic used was the ANOVA, and all post hoc comparisons were
performed using Fisher’s LSD post hoc tests. The independent variables were genetic mutation
(wild type or BA-2 KO), drug treatment (nicotine or saline), and day of treatment (14 days). The
dependent variable was number of horizontal line crosses. Two different time points were
analyzed: The 14-day sensitization training sessions and the nicotine challenge. For sensitization
training, (see Figure 4) a 2x2x14 three-way repeated measures ANOVA revealed a significant
main effect of day of testing (F(13,21) = 3.93, p<.001) and a significant two-way interaction of
Genetic Mutation x Week of testing (F(13,21) = 4.46, p<.001). After 14 days of sensitization
training, wild type controls did demonstrate significant increases in locomotor activity by days
13 and 14. Although BA-2 KOs did eventually sensitize to nicotine, this was not revealed until
days 13 and 14 of sensitization training.
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Figure 4. Fourteen-day sensitization training.
For the nicotine challenge (see Figure 5), a 2 x 2 ANOVA revealed a significant main
effect of Genetic Mutation (F (1, 22) = 15.95, p<.001). BA-2 KO mice administered nicotine did
not demonstrate a significant increase in activity and thus did not express sensitization to
nicotine. Wild-type controls that were administered nicotine demonstrated a significant increase
in activity after a 7-day abstention period, demonstrating that wild-type animals given nicotine
demonstrate both induction and expression of nicotine sensitization.

Figure 5. Nicotine challenge for 14-day sensitization training.
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BDNF Analysis
In experiment one, a 2 x 2 ANOVA (see Figure 6) revealed a significant interaction of
Genetic Mutation x Adolescent Drug Treatment (F(1,13) = 5.82, p<.031). Wild-type animals
treated with nicotine demonstrated a significant increase of BDNF over all other groups.
Nicotine appears to have produced a significant decrease of BDNF in the BA-2 KO group.
Likewise, in Experiment two, a 2 x 2 ANOVA (see Figure 7) revealed a significant interaction of
Genetic Mutation x Adolescent Drug Treatment (F(1,13) = 5.82, p<.031). Wild-type animals
treated with nicotine demonstrated a significant increase of BDNF over all other groups.
Nicotine appears to have produced a significant decrease of BDNF in the BA-2 KO group (F (1,
15) = 4.73, p<.04). Like Experiment one, wild-type controls treated with nicotine demonstrated a
significant increase of BDNF over all other groups, and nicotine appears to have produced a
significant decrease of BDNF in BA-2 KOs.

Figure 6. BDNF analysis for experiment 1.
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Figure 7. BDNF analysis for experiment 2.
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CHAPTER 4
DISCUSSION
The purpose of the current study was to examine the effects of nicotine exposure on
locomotor activity and NAcc BDNF in adolescent BA-2 KO mice. The results demonstrate that
β-arrestin 2 is an important protein in nicotine locomotor sensitization because adolescent BA-2
KO mice administered nicotine did not reach activity levels of wild type controls administered
nicotine. These results contrast with a past study examining the effects of cocaine on adult BA-2
KOs that showed no significant change in locomotor activity in response to cocaine, which is in
the same drug family as nicotine (Bohn et al., 2004). The difference in results between the
current study and that of Bohn and colleagues point to an important difference in the synaptic
mechanism between cocaine and nicotine, as cocaine is primarily an inhibitor of the DA
transporter, whereas nicotine increases presynaptic DA release and blocks the DA presynaptic
autoreceptor (Wonnacott, Sidhpura, & Balfour, 2005). Based on the current results, it appears
that β-arrestin-2 may play a more important role in sensitization to nicotine as compared to
cocaine. Interestingly, BA-2 KOs did eventually sensitize to nicotine over a 14-day period,
showing that absence of β-arrestin-2 reduced nicotine sensitization, but it did not eliminate
sensitization to the drug. On the nicotine challenge in both experiments, wild-type controls given
nicotine demonstrated expression of sensitization, whereas BA-2 KO mice did not express
sensitization to nicotine. This result appears to show that although β-arrestin-2 plays a role in
the induction of sensitization, but its absence blocks the expression of sensitization after an
abstinence period. Finally, BDNF results showed that adolescent BA-2 KO mice receiving
nicotine show a decrease in BDNF compared to all other groups, which appears to be congruent
with their behavior on the nicotine challenge. This decrease in BDNF appears to support the
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hypothesis that removal of β-arrestin 2 would produce decreased cellular response to nicotine,
which may be due to one of several mechanisms. First, the lack of ability to remove the agonist
from the receptor (receptor desensitization) could produce over-activity in the cell and eventually
result in cell death; or it could be that the lack of β-arrestin 2 resulted in an overall decrease in
cellular response due to its direct role in phosphorylation of the ion channel; or it could be that
increasing activity of the D2 receptor, known to be an inhibitory receptor, may produce an
overall decreased response to nicotine. At this point, clearly, much work is to be done to discover
the mechanism underlying the effects of nicotine on BDNF in BA-2 KO mice. Impressively,
nicotine did produce a significant increase in BDNF in both Experiment 1 and 2 in wild types
even after a 7-day drug washout, and the effect of BDNF observed in BA-2 KOs was replicated
across both experiments.
Nicotine Sensitization
Nicotine sensitization occurs when an animal demonstrates an increased behavioral
response to repeated administrations of nicotine. Nicotine is unique when analyzing locomotor
sensitization in the psychostimulant drug class because an increase in the behavioral response to
this drug occurs after an initial hypoactive response. Previous studies in both rats and mice have
repeatedly shown that a period of hypoactivity is subsequently followed by a robust increase in
locomotion that surpasses the activity levels of controls (Domino, 2001; Schoffelmeer, De Vries,
Wardeh, van de Ven, & Vanderschuren, 2002). In the current study, it appears that mice
demonstrated a more robust hypoactive response to nicotine than is typical in rats. In fact, wildtype mice receiving nicotine did not increase in activity to the levels of saline-treated wild-type
controls until the 8th day of drug treatment in Experiment 2. Whether this is a species difference
in locomotor behavior, or it reflects species differences in the dopaminergic system between
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mice and rats is not known at this time. However, it can be assumed that the behavioral
responses that are observed reflect neuronal changes in the brain in response to nicotine,
particularly relating to the relationship between nicotine administration and increases in DA
levels in the NAcc (Balfour, 2004; Di Chiara et al, 2004). Thus, we can infer that the persistent
hypoactive response to nicotine may be due to a species difference in the way the NAcc responds
to the drug. Additionally, a relatively high dose of nicotine was used in this study (0.5 mg/kg free
base) and it may be that C57/B6 mice are more sensitive to nicotine than other strains of mice as
well as rats, at least in the initial hypoactive response to the drug. There is evidence that mice
respond to nicotine differently depending upon strain; however, these differences are not
necessarily caused by differences in the nicotinic system (Overstreet, 1995; Robinson et al.,
1996). Somewhat consistent with this hypothesis, C57BL/6 mice were the most sensitive to oral
nicotine consumption (Robinson, Marks, & Collins); however, this study used a different route
of administration than that used in the current study.
Pierce and Kalivas (1997) define the initiation of behavioral sensitization as events that
lead to changes in the brain, whereas the expression of sensitization is the behavioral change
from initiation that results in a behavioral response to the drug after a drug-free abstinence
period. In Experiment 1, after 7 days of nicotine administration, both wild-types and BA-2 KOs
receiving nicotine showed initiation of sensitization in that both groups increased activity from
day 1 to day 7 of treatment. However, only wild types demonstrated expression of sensitization
on the nicotine challenge. After 14 days of nicotine treatment, both wild types and BA-2 KOs
again demonstrated initiation of sensitization in comparing day 1 to day 14 of activity, and both
groups demonstrated an increase in activity relative to wild-type controls and BA-2 KOs that
received saline. Results from the challenge showed that wild-type mice continued to express
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sensitization to nicotine as in Experiment 1, but knockout mice did not. Therefore, it can be
inferred that lacking β-arrestin 2 blocks expression of nicotine sensitization after an abstention
period, indicating that the β-arrestin-2 protein is important in the persistent changes produced by
nicotine in locomotor sensitization. This is particularly important because research has shown
that nicotine receptor activation results in long-term expression of sensitization even after a
relatively short period of nicotine administration (Miller et al., 2001). Therefore, it appears that
the β-arrestin-2 protein plays an important role in the maintenance of sensitization to nicotine.
Based on the co-localization of β-arrestin-2 with D2 receptors, the current results also
were informative relative to the role of the D1 and D2 receptors in nicotine sensitization. Past
research has analyzed the role of the D1 and D2 receptor families and their involvement in
nicotine locomotor sensitization. For example, systemic administration of the D1 antagonist SCH
23390 or the D2 antagonist spiperone has been shown to block the locomotor stimulant effect of
nicotine infusions into the VTA or NAcc (Kita, Okamoto, & Nakashima, 1992). Additionally,
both SCH 23390 and the D2 antagonist eticlopride have been shown to block nicotine
sensitization when nicotine was administered intravenously (Sziraki, Sershen, Hashim, & Lajtha,
2002). However, there is very little information regarding DA antagonist effects on sensitization
to systemic nicotine injections. Regarding other psychostimulants, the majority of evidence
points to the importance of the D1, but not the D2 receptor, in sensitization to amphetamine
(Vezina & Stewart, 1989a). However, in the current study, it appears that the D2 receptor plays a
role in nicotine sensitization. Compared to wild-type controls administered nicotine, BA-2 KOs
receiving nicotine demonstrated significantly lower levels of activity until they reached day 8 of
treatment, but their level of activity did not increase any further throughout the 14 days of
behavioral testing. Although BA-2 KOs demonstrated sensitization to nicotine, these animals did
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not reach the activity levels of control animals as rapidly as wild types receiving nicotine, nor
were they as active as wild-type controls by the end of testing. Because the D2 receptor has been
shown to be an inhibitory receptor and β-arrestin 2 is a regulator of G-protein coupling at this
receptor, it appears that absence of this protein may decrease the rewarding effects of nicotine,
making it a possible clinical target for the treatment of nicotine addiction.
There have been other studies using different behavioral paradigms to study the roles of
D1 and D2 receptors in nicotine's rewarding properties. For example, Spina and colleagues
(2006) examined the roles of these receptors in nicotine CPP and used D1 and D2 antagonists by
injecting them directly into the NAcc core and shell. Results showed that nicotine does generate
a conditioned place preference using either a 0.4 or 0.6 mg/kg dose injected subcutaneously. The
D1 antagonist SCH 39166 did not affect CPP when injected into the core but did alleviate
nicotine-induced conditioned place preference when injected into the shell. The D2 antagonist
L-sulpiride did not affect nicotine-induced CPP when injected into the shell. These results
demonstrate the importance of the D1 receptors in the NAcc core and shell relative to the
rewarding properties of nicotine.
Nicotine and the µ-opioid Receptor
Although β−arrestin 2 has been shown to be co-localized with the D2 receptor, it has also
been shown to be co-localized with the µ opiate receptor, which may be important in explaining
the effects observed here. Past studies have shown an interaction between nicotine and opiate
receptors, although nicotine is not in the opiate drug family. Nicotine has been shown to
generate antinociception through activation of nAChRs, and it is believed that the µ-opioid
receptor is involved in tolerance to nicotine (Galeote, Keiffer, Maldonado, & Berrendero, 2006).
Because β-arrestin 2 is involved in both the DA and the opioid system, the µ-receptor may play a
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role in other behavioral responses to nicotine. Galeote and colleagues examined this role in
C57BL/6 mice as controls and µ-receptor knockout mice. Results showed that chronic nicotine
treatment produced tolerance antinociception in both wild types and in knockouts; however,
tolerance developed faster in the µ-receptor knockouts than in controls (Galeote et al), and µ
receptors down regulated in the basal ganglia, demonstrating that the mu receptor plays a role in
the development of tolerance to nicotine's antinociceptive effects, and opiate antagonists such as
naloxone have been shown to block this effect (Campbell, Taylor, & Tizabi, 2007).
Additionally, other studies have shown that pretreatment with the opiate antagonist naloxone can
block nicotine-induced conditioned place preference (Zarrindast et al. 2003), and in µ opioid
receptor knockout mice nicotine sensitization has been shown to be reduced (Yoo et al., 2004). It
appears that the µ receptor may play a mediating role in nicotine sensitization, thus, knockout of
the β-arrestin 2 protein may enhance µ opiate signaling. It remains that increases of µ opiate
receptor signaling would produce an increased, not decreased, locomotor response to nicotine.
On the other hand, it has been shown that β-arrestin-2 is important in signal transduction,
meaning that β-arrestin 2 can be involved in direct phosphorylation of the ion channel in the
signal transduction pathway, and this may be a key point in explaining the role of β-arrestin 2 in
nicotine sensitization.
BDNF Analysis
Research has shown that neurotrophic factors play a role in addiction and positively
correlate with increased locomotor activity after either amphetamine or cocaine administration
(Tsai, 2007), but there is not any information as to whether nicotine induces increases in BDNF
that correlate with increases in activity produced by nicotine. As hypothesized, in the current
study, adolescent BA-2 KO mice that received nicotine demonstrated a decrease in NAcc BDNF
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compared to all other groups. Control animals receiving nicotine showed an increase in BDNF
that is somewhat consistent with the literature examining BDNF in rats, as past research has
shown an increase in the genetic expression of BDNF after chronic nicotine treatment, although
this effect was shown within 48 hours of drug administration using higher doses than that used in
the present study (French et al., 1999; Fumagalli et al., 2004). Research in rats has shown that
even a single dose of cocaine can result in an increase in BDNF and chronic administration can
produce increase in BDNF in the PFC (Le Foll, Diaz, & Sokoloff, 2005). Rats infused with
BDNF in the NAcc or VTA have shown demonstrated an enhanced response to cocaine when
compared to rats that were not infused with BDNF (Horger et al., 1999). This result points to the
importance of the relationship between psychostimulants and BDNF. In the current study it can
be inferred that there was a significant decrease in BDNF because the absence of the β-arrestin 2
protein prevented long-term reward from nicotine. Whether BDNF plays a direct or modulating
role in the rewarding effects of nicotine is not known, but based on the fact that BDNF is
important in synaptic maintenance and development and the changes observed were at least
congruent with the behavioral response, certainly implies BDNF may play a role in nicotine drug
reward.
Adolescent Nicotine Exposure
There has been very little research performed on β-arrestin 2 and its role in
psychostimulant sensitization. In the current study, adolescent C57/B6 mice appear to be
different from adolescent rats in that the wild-type controls did not sensitize to nicotine during 7
days of nicotine administration, a finding that has been consistent in the literature examining the
effects of nicotine in adolescent rats (Collins, Montano, & Izenwasser, 2004; Collins, Wade,
Ledon, & Izenwasser, 2004; Domino, 2001; Wilmouth & Spear, 2006).
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Research has shown that adolescent mice exposed to nicotine show differences in
behavioral responses in early, middle, and late adolescent mice (Adriani et al., 2004).
Adolescent CD-1 mice allowed access to oral nicotine showed a decrease in cortisol levels after
nicotine consumption and showed a preference for nicotine when given free choice between
water and nicotine (Adriani, Macri, Pacifici, & Laviola, 2002a). Furthermore, later research
examining differences between early, late, and middle adolescent CD-1 mice demonstrated that
mice showed a preference for nicotine in early adolescence, no greater preference for water or
nicotine during middle adolescence, and an avoidance of nicotine during late adolescence. When
nicotine concentrations were reduced, only early adolescent mice increased their nicotine
consumption to compensate (Adriani, Marci, Pacifici, & Laviola, 2002b). Studies examining the
effects of adolescent nicotine exposure on subsequent adult cocaine exposure have found that
repeated nicotine administration causes a decrease in cocaine’s rewarding effects as measured by
CPP, but an increase in its locomotor activating effects (Kelley & Rowan, 2004). Thus, it
appears that adolescent nicotine exposure can produce persistent changes in adult brain function
that may be important in predicting addiction to psychostimulants in adulthood.
Klein and colleagues (2004) examined the effects of oral nicotine consumption in
adolescent C57BL/6J mice. Six doses were used and mice were allowed access to saccharin
solution and one of the six doses for 7 days. Males and females were assessed for weight gain,
food consumption, fluid intake, and voluntary nicotine consumption. Results showed that
animals receiving nicotine showed no gender differences in weight gain, food consumption, or
fluid intake. However, female adolescent mice consumed more nicotine than males when oral
nicotine consumption was taken into account as a percentage of fluid intake (Klein, et al).
Although only males were used in the current study and nicotine was administered by the
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experimenter and not administered voluntarily, it can be inferred that male and female mice
would demonstrate different behavioral responses to nicotine when administered subcutaneously.
Kota and colleagues (2007) examined the effects of nicotine in adolescent and adult male
IRC mice on analgesia, locomotor activity, CPP, and withdrawal. Results showed that
adolescent and adult animals differed in all areas examined. Adolescent mice demonstrated CPP
at lower doses than adults (.05 and .01 mg/kg as compared to .7 and 1.0 mg/kg), fewer physical
signs of withdrawal, and lower activity levels than adults. Adolescents were also less sensitive
to tail-flick testing and demonstrated a higher tolerance during hot plate testing than adults.
These results suggest that adolescent IRC mice demonstrate a higher sensitivity to nicotine than
adults. However, like BA-2 KOs receiving nicotine, adolescent IRC mice demonstrated lower
levels of activity demonstrating that not only may there be species differences but strain
differences as well.
Limitations of the Current Study
One limitation of the current study is that wild-type mice receiving nicotine did not
sensitize in 7 days of treatment, which has been shown in the literature (Collins, Montano,
Izenwasser, 2004; Collins, Wade, Ledon, & Izenwasser, 2004; Domino, 2001; Wilmouth &
Spear, 2006). However, it is unclear if this finding is related to strain differences because
previous research has shown that this particular strain of mice is more sensitive to nicotine
(Robinson, Marks, & Collins, 1996). Therefore, this finding could be related to sensitivity of this
strain and dosing could have been too high or to low to induce sensitization in 7 days. Also, the
current study used a relatively low number of BA-2 KOs and increasing the number of BA-2
KOs used in the study would be beneficial to learning more about locomotor behavior and
protein expression in the brain in these animals. Furthermore, only males were used in the
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current study and research has shown that males and females respond differently to nicotine
(Klein et al., 2004). Examining sex differences in BA-2 KOs could provide insight into
fundamental differences between males and females that can affect response to nicotine.
Future Studies
In light of the limited amount of research examining the effects of nicotine on locomotor
sensitization in adolescent mice, and particularly in BA-2 KO mice, future research could
examine a wide range of areas. Examining dose-response in BA-2 KO mice would be beneficial
as the current study only used one dose. A dose-response curve could provide valuable
information surrounding how activity changes based on the amount of nicotine administered.
Furthermore, various doses could be given during early, middle, and late adolescence to
determine how sensitivity to nicotine changes throughout adolescence.
Self-administration of nicotine could also provide valuable information about the
mechanisms surrounding DA transmission and nicotine dependence and withdrawal in the
absence of β-arrestin 2. Self-administration could examine if BA-2 KOs would become
dependent on nicotine and increase self-administration overtime. This is important to
understanding more about how β-arrestin 2 contributes to reward because it can be inferred that
BA-2 KOs would only self-administer nicotine if there was a positive benefit from the drug.
Because previous research has shown that some strains of adolescent mice do not demonstrate
withdrawal symptoms, it would be important to determine if symptoms of withdrawal would be
present in BA-2 KOs if access to nicotine ceased.
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Conclusions
The current study provides valuable information about the role of β-arrestin 2 in nicotine
sensitization. β-arrestin 2 is important in G-protein regulation, signal transduction, and receptor
desensitization in both and DA and opiate function. Adolescent nicotine use generates not only
nicotine dependence but also increases consumption and makes cessation in adulthood more
difficult. The results of the current study point to β-arrestin 2 as playing an important role in the
neural adaptations related to nicotine administration, and it appears that knocking out the βarrestin 2 protein reduces the activating effects of nicotine in animals. This finding is important
as it points to the importance of the β-arrestin 2 protein in nicotine addiction, and this study is
the first in what hopefully will be a series of studies analyzing the role of this protein in
addiction. Finally, it is clear there is an interaction between the β-arrestin 2 protein and brain
plasticity via BDNF in the NAcc, and future studies will be designed to analyze the mechanisms
of this important interaction.
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